Analysts See $-0.22 EPS for Sierra Oncology, Inc. (SRRA); Last Week BioScrip, Inc. (BIOS) Coverage

April 17, 2018 - By Lawrence Diaz

BioScrip, Inc. (NASDAQ:BIOS) Logo

Among 6 analysts covering BioScrip (NASDAQ:BIOS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The company was upgraded on Thursday, August 10 by SunTrust. SunTrust maintained the stock with “Buy” rating in Wednesday, December 20 report. Barrington maintained BioScrip, Inc. (NASDAQ:BIOS) rating on Wednesday, April 11. Barrington has “Buy” rating and $3.5000 target. SunTrust maintained the stock with “Buy” rating in Thursday, March 8 report. The firm has “Buy” rating given on Tuesday, August 11 by SunTrust. The company was maintained on Wednesday, August 12 by Dougherty & Company. Lake Street initiated the shares of BIOS in report on Tuesday, January 3 with “Buy” rating. Jefferies maintained the shares of BIOS in report on Wednesday, August 9 with “Buy” rating. Jefferies maintained BioScrip, Inc. (NASDAQ:BIOS) on Tuesday, July 25 with “Buy” rating. SunTrust maintained the stock with “Buy” rating in Thursday, November 2 report. See BioScrip, Inc. (NASDAQ:BIOS) latest ratings:

11/04/2018 Broker: Barrington Rating: Buy New Target: $3.5000 Maintain
08/03/2018 Broker: SunTrust Rating: Buy New Target: $3.25 Maintain
20/12/2017 Broker: SunTrust Rating: Buy New Target: $3.5 Maintain
02/11/2017 Broker: SunTrust Rating: Buy New Target: $3.0 Maintain
02/11/2017 Broker: Jefferies Rating: Buy New Target: $4.0 Maintain

Analysts expect Sierra Oncology, Inc. (NASDAQ:SRRA) to report $-0.22 EPS on May, 8.They anticipate $0.04 EPS change or 15.38% from last quarter’s $-0.26 EPS. After having $-0.20 EPS previously, Sierra Oncology, Inc.’s analysts see 10.00% EPS growth. The stock increased 6.00% or $0.11 during the last trading session, reaching $1.94. About 293,530 shares traded. Sierra Oncology, Inc. (NASDAQ:SRRA) has risen 38.93% since April 17, 2017 and is uptrending. It has outperformed by 27.38% the S&P500.

BioScrip, Inc. provides home infusion services in the United States. The company has market cap of $339.67 million. The firm engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It currently has negative earnings. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

The stock increased 3.10% or $0.08 during the last trading session, reaching $2.66. About 241,789 shares traded. BioScrip, Inc. (NASDAQ:BIOS) has risen 42.70% since April 17, 2017 and is uptrending. It has outperformed by 31.15% the S&P500.

Investors sentiment increased to 1.18 in Q4 2017. Its up 0.13, from 1.05 in 2017Q3. It is positive, as 12 investors sold BioScrip, Inc. shares while 28 reduced holdings. 19 funds opened positions while 28 raised stakes. 104.07 million shares or 0.29% less from 104.38 million shares in 2017Q3 were reported. M&T Natl Bank Corp has 0% invested in BioScrip, Inc. (NASDAQ:BIOS). State Street Corporation invested 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). American International Gp Incorporated holds 0% or 78,248 shares in its portfolio. Magnetar Llc holds 21,875 shares. Invesco stated it has 354,660 shares. Thompson Siegel & Walmsley Lc reported 0% stake. Principal Financial Gru Incorporated has invested 0% in BioScrip, Inc. (NASDAQ:BIOS). Continental Advsr Lc holds 172,800 shares or 0.11% of its portfolio. Sei stated it has 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). Brighton Jones Ltd holds 22,851 shares or 0.01% of its portfolio. Benjamin F Edwards And stated it has 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). Tower Cap (Trc) has invested 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). Portolan Capital Mngmt Ltd Liability Co holds 362,323 shares or 0.12% of its portfolio. Salzhauer Michael has 24,075 shares. Gsa Cap Ltd Liability Partnership holds 0.05% in BioScrip, Inc. (NASDAQ:BIOS) or 254,306 shares.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response therapeutics for the treatment of patients with cancer in the United States and internationally. The company has market cap of $138.49 million. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It currently has negative earnings. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage.

BioScrip, Inc. (NASDAQ:BIOS) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>